Combination of ultra-low-dose isotretinoin and antihistamines in treating Morbihan disease – a new long-term approach with excellent results and a minimum of side effects

Abstract

Morbihan disease is characterized by erythema and solid edema in the two upper thirds of the face. Underlying factors are an imbalance in lymphatic drainage, chronic inflammation, and mast cells leading to fibrosis. Treatment options known thus far have led to unsatisfactory results and have often been associated with a greater risk of side effects; even invasive options have been applied. This study presents four patients treated with a combination of ultra-low-dose isotretinoin and antihistamines for a mean duration of 14 months. While no side effects other than dryness of the lips were noted, a significant reduction of the erythema and edema could be observed in all patients. Specialists evaluated the treatment’s success by photodocumentation and measured a 91.5% alleviation of erythema, and 85% reduction of edema, respectively. Based on these results, this new regimen in the therapeutic approach toward Morbihan disease is suggested due to its anti-inflammatory features and low risk of side effects.

Keywords:

• Morbihan disease
• treatment options
• ultra-low-dose isotretinoin
• antihistamines

Disclosure statement

M. Schaller has been a member of the Bayer, Galderma and Marpinion advisory boards within the past 3 years and has received lecture fees from AbbVie, Bayer Healthcare, Galderma and La Roche‐Posay.